Laurus Labs share price: Sharekhan retains Buy recommendation with a revised price target of Rs 450
Sharekhan had an interaction with Laurus Labs management and their commentary was positive, pointing towards a robust growth outlook. Laurus’ formulations business is on a strong growth footing, backed by a higher quantum of launches in the US as well as opportunities from in-licensing of products, in addition to traction in anti-retrovirals (ARVs).

Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology: Image taken from companies website